More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$267464247
EPS
1.4
P/E ratio
118.2
Price to sales
15.97
Dividend yield
--
Beta
0.788361
Previous close
$7.42
Today's open
$7.42
Day's range
$7.14 - $7.42
52 week range
$4.80 - $8.95
show more
CEO
Arun Menawat
Employees
131
Headquarters
Mississauga, ON
Exchange
NASDAQ Capital Market
Shares outstanding
36626844
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Profound Medical to Participate in the Stifel 2026 Healthcare Conference
TORONTO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced that its President, Richard Fabian, will present at the Stifel 2026 Healthcare Conference on Thursday, November 12, 2026 at 8:40 a.m. Eastern Time in NYC.
GlobeNewsWire • Nov 9, 2026

What Profound Medical (PROF) Said on Its Q3 Earnings Call
Profound Medical NASDAQ: PROF reported an 86% increase in third-quarter revenue and raised its full-year revenue outlook, as sales of its TULSA-PRO equipment helped drive growth ahead of a planned leadership transition.
MarketBeat • Nov 6, 2026

Profound Medical (PROF) Expected to Beat Earnings Estimates: Should You Buy?
Profound Medical (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Nov 5, 2026

Profound Medical (PROF) Reports Q3 Loss, Beats Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.26 per share a year ago.
Zacks Investment Research • Nov 6, 2026

Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth
Gross margin reaches 78%; cash used in operating activities declines 56% sequentially Profound expects full-year 2026 revenue to be at least $25.0 million; minimum gross margin projection for the year remains at 70% or higher New Cook Medical agreement positions TULSA-PRO ® within the iMRI Suite offering through Cook Medical's Copernicus™ program, expanding Profound's commercial reach across the United States Richard Fabian appointed as CEO, effective January 14, 2027; Arun Menawat to transition to Executive Chairman; Matthew Sobczyk becomes permanent CFO; Jason Mills joins Board TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today reported financial results for the third quarter ended September 30, 2026. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).
GlobeNewsWire • Nov 5, 2026

Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth
New distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical's Copernicus™ program, expanding Profound's commercial reach
GlobeNewsWire • Oct 30, 2026

Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research • Oct 30, 2026

Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let's Huddle' Webinar
TORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that Emmy Award-winning television host, health advocate and decorated U.S. Navy veteran, Montel Williams, will join the next Let's Huddle webinar for a discussion with its host, Leonard Wheeler, on November 5, 2026, at 3:00 p.m. ET. Mr. Williams will share his personal perspectives on health advocacy, resilience, informed healthcare decisions and the importance of protecting quality of life.
GlobeNewsWire • Oct 22, 2026

TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMRI”) Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real-world performance, clinical differentiation, and platform expansion potential of the TULSA Procedure™ performed using the TULSA-PRO ® system.
GlobeNewsWire • Oct 14, 2026

Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?
The mean of analysts' price targets for Profound Medical (PROF) points to a 58.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research • Oct 14, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Profound Medical Corp. commission-free¹. Build wealth for the long term using automated trading and transfers.